We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Selexis SA and Teneobio, Inc. have entered into a second services agreement to expand Teneobio’s oncology pipeline of Human Heavy-Chain Antibodies (UniAbs), a new class of multi-specific biologics. Teneobio will utilize Selexis’ SUREtechnology Platform
Alvotech and Fuji Pharma have entered an exclusive agreement for the development and commercialization of biosimilars in Japan. Fuji is acquiring a 4.2% stake in Alvotech for approximately $50 million